Uncategorized
Aerie Pharmaceuticals submits NDA for Rhopressa
Aerie Pharmaceuticals submitted a new drug application to the FDA for Rhopressa, a once-daily eye drop designed to lower IOP in patients with glaucoma or ocular hypertension.The application includes results of the Rocket 1 and Rocket 2 studies, the first two phase 3 registration trials for Rhopressa (netarsudil ophthalmic solution 0.02%), according to a press release from Aerie.